Abstracts tagged "Sjogren’s syndrome"

Abstract Number: 517 • 2012 ACR/ARHP Annual Meeting
Overexpression of BMP6 Is Associated with Loss of Salivary Gland Activity in Sjögren’s Syndrome Patients and Mice
Hongen Yin¹, Javier Cabrera-Perez¹, Zhennan Lai¹, Drew Michael², Melodie Weller¹, Bill Swaim¹, Noreen Rana¹, Xibao Liu¹, Ilias Alevizos³, Indu Ambudkar⁴ and John A. Chiorini¹, ¹Mptb, NIH/NIDCR, Bethesda, MD, ²Mptb, NIDCR, Bethesda, MD, ³Sjogren's Clinic, NIDCR/ NIH #10 1N110, Bethesda, MD, ⁴Molecular Physiology and Therapeutics Branch, NIDCR, Bethesda, MD
Background/Purpose: A hallmark of Sjögren’s syndrome (SS) is the loss of activity in secretory epithelia, specifically the larcrimal and salivary glands. The mechanism(s) driving this…
Abstract Number: 2671 • 2012 ACR/ARHP Annual Meeting
A Genome-Wide Association Study Establishes Muliple Susceptibility Loci for Sjögren’s Syndrome
Christopher J. Lessard¹, He Li², Indra Adrianto³, John A. Ice³, Roland Jonsson⁴, Gabor G. Illei⁵, Maureen Rischmueller⁶, Gunnel Nordmark⁷, Xavier Mariette⁸, Corinne Miceli-Richard⁹, Marie Wahren-Herlenius¹⁰, Torsten Witte¹¹, Michael T. Brennan¹², Roald Omdal¹³, Patrick M. Gaffney³, James A. Lessard¹⁴, Wan-Fai Ng¹⁵, Nelson L. Rhodus¹⁶, Barbara M. Segal¹⁷, R. Hal Scofield¹⁸, Judith A. James¹⁹, Juan-Manuel Anaya²⁰, John B. Harley²¹, Courtney G. Montgomery³ and Kathy Moser Sivils¹⁹, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma CIty, OK, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Broegelmann Research Laboratory, the Gade Institute, University of Bergen, Bergen, Norway, ⁵Sjogren's Clinic, NIDCR/ NIH, Bethesda, MD, ⁶Rheumatology Department, Queen Elizabeth Hospital, Adelaide, Australia, ⁷Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ⁸Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ⁹Hopital Bicêtre, Le Kremlin Bicêtre, France, ¹⁰Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ¹¹Clinical Immunology and Rheumatology, Medical University Hannover, Hanover, Germany, ¹²Nidcr NIH, Carolinas Medical Center, Charlotte, NC, ¹³Department of Internal Medicine, Stavanger university Hospital, Stavanger, Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ¹⁴Valley Bone and Joint Clinic, Grand Forks, ND, ¹⁵Musculoskeletal Research Group Institute of Cellular Medicine, Newcastle University, Newcastle University, Newcastle, England, ¹⁶University of Minnesota, Minneapolis, MN, ¹⁷Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁸Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁰School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ²¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH
Background/Purpose: Sjögren’s syndrome (SS) is a common, clinically heterogeneous autoimmune disease characterized by exocrine gland dysfunction that involves both innate and adaptive immune responses. A…
Abstract Number: 2185 • 2012 ACR/ARHP Annual Meeting
Prevalence of Severe Extra-Glandular Manifestations in a Large Cohort of Patients with Primary Sjögren’s Syndrome
Chiara Baldini¹, Pasquale Pepe², Luca Quartuccio³, Roberta Priori⁴, Elena Bartoloni Bocci⁵, Alessia Alunno⁶, Serena Colafrancesco⁷, Angelica Gattamelata⁸, Marta Maset⁹, Mariagrazia Modesti⁷, Antonio Tavoni¹⁰, Salvatore De Vita⁹, Roberto Gerli⁵, Guido Valesini⁷ and Stefano Bombardieri¹¹, ¹University of Pisa, Rheumatology Unit, Pisa, Italy, ²Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ³Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ⁴Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy, ⁵Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Perugia, Italy, ⁶Clinical and Experimental Medicine, Rheumatology Unit, University of Perugia, Perugia, Italy, ⁷Rheumatology Unit, Sapienza University of Rome, Rome, Italy, ⁸Sapienza University of Rome, Rome, Italy, ⁹Rheumatology Clinic, DSMB, University of Udine, Italy, Udine, Italy, ¹⁰University of Pisa, Immunoallergology Unit, Pisa, Italy, ¹¹Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: i) to describe the clinico- serological features of a cohort of 1115 patients with primary Sjögren’s syndrome (pSS); ii) to assess the prevalence of systemic extra-glandular…
Abstract Number: 518 • 2012 ACR/ARHP Annual Meeting
Spontaneous Sialadenitis Like Sjögren’s Syndrome in Orphan Nuclear Receptor γt (RORγt) Transgenic Mice
Mana Iizuka¹, Hiroto Tsuboi¹, Hiromitsu Asashima¹, Yuya Kondo¹, Satoru Takahashi², Isao Matsumoto¹ and Takayuki Sumida¹, ¹Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan, ²Department of Anatomy and Embryology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan
Background/Purpose: The nuclear receptors retinoic-acid-receptor-related orphan receptors gt (RORγt) is required for the generation of Th17 cells expressing the proinflammatory cytokine IL-17. Th17 cells expressing…
Abstract Number: 2672 • 2012 ACR/ARHP Annual Meeting
Genome-Wide Association Analysis Reveals Genetic Heterogeneity of Sjögren’s Syndrome (SS) According to Specific Subphenotypes and Ancestry
Lindsey A. Criswell¹, Kimberly E. Taylor², Caitlin McHugh³, Cathy Laurie³, Kimberly Doheny⁴, Mi Y. Lam², Joanne Nititham⁵, Laura Bierut⁶, Emily L. Harris⁷, Alan N. Baer⁸, Stephen Challacombe⁹, Yi Dong¹⁰, Hector Lanfranchi¹¹, Morten Schiodt¹², M. Srinivasan¹³, Susumu Sugai¹⁴, Hisanori Umehara¹⁵, Frederick B. Vivino¹⁶, Zhao Yan¹⁷, Stephen Shiboski², Troy Daniels¹⁸, John S. Greenspan¹⁹, Caroline Shiboski¹⁹ and SICCA²⁰, ¹Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California, San Francisco, San Francisco, CA, ²University of California, San Francisco, San Francisco, CA, ³University of Washington, Biostatistics, Seattle, WA, ⁴Center for Inherited Disease Research, Baltimore, MD, ⁵Medicine, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ⁶Psychiatry, Washington University, St. Louis, MO, ⁷National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁸Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Kings College London, London, United Kingdom, ¹⁰Dept of Rheumatology, Peking Univ Med Coll Hospital, East City Beijing, China, ¹¹University of Buenos Aires, Buenos Aires, Argentina, ¹²Righospitalet, Copenhagen, Denmark, ¹³Aravind Eye Hospital, Madurai, India, ¹⁴Kanazawa Medical University, Ishikawa, Japan, ¹⁵Internal Medicine, Division of Hematology and Immunology, Kanazawa Medical University, Kanazawa, Japan, ¹⁶Medicine, Penn Presbyt Med Ctr, Philadelphia, PA, ¹⁷Department of Rheumatology, Peking Union Medical College Hospital, Beijing, China, ¹⁸Orofacial Sciences, Box 0422, UCSF Schools of Medicine & Dentistry, San Francisco, CA, ¹⁹Orofacial Sciences, University of California, San Francisco, San Francisco, CA, ²⁰San Francisco, CA
Background/Purpose: Our goal is to define the contribution of genetic factors to SS and related subphenotypes. Methods: We studied 2,459 participants in the Sjögren’s International…
Abstract Number: 2189 • 2012 ACR/ARHP Annual Meeting
Efficacy of Belimumab On Non-Malignant Parotid Swelling and Systemic Manifestations of Sjögren’s Syndrome: Results of the Beliss Study
Salvatore De Vita¹, Raphaèle Seror², Luca Quartuccio³, Frederic Desmoulins⁴, Sara Salvin⁵, Gabriel Baron⁶, Martina Fabris⁷, Philippe Ravaud⁸, Miriam Isola⁹ and Xavier Mariette¹⁰, ¹Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ²Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, LE Kremlin-Bicetre, France, ³Rheumatology Clinic, DSMB, University of Udine, Udine, Italy, ⁴Rheumatology, Université Paris-Sud, Le Kremlin Bicêtre, Le Kremlin Bicetre, France, ⁵Rheumatology Clinic, DSMB, University of Udine,, Udine, Italy, ⁶Epidemiology & Clinical Research, Groupe Hospitalier Bichat-Claude Bernard, Paris, France, ⁷Institute of Clinical Pathology, Udine, Italy, ⁸Epidemiology, Université Paris-Descartes, Paris, Paris, France, ⁹Institute of Statistics, DSMB, University of Udine, Udine, Italy, ¹⁰Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France
Background/Purpose: to report the effects of anti-BAFF/BLyS antibody belimumab (BEL) on the different ogan manifestations of primary Sjögren’s syndrome (pSS), by evaluating the ESSDAI score…
Abstract Number: 519 • 2012 ACR/ARHP Annual Meeting
Sex-Specific Regulatory T Cell Dysfunction in a Mouse Model of Sjögren Syndrome
Scott M. Lieberman¹, Portia A. Kreiger² and Gary A. Koretzky³, ¹Pediatrics, Div Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Pathology, Nemours/A.I. DuPont Hospital for Children, Wilmington, DE, ³Medicine, University Pennsylvania, Philadelphia, PA
Background/Purpose: CD4+Foxp3+ regulatory T cells (Tregs) are a specialized population of lymphocytes which prevent autoimmunity in normal hosts. Treg dysfunction has been implicated in autoimmunity; however results…
Abstract Number: 2673 • 2012 ACR/ARHP Annual Meeting
Sibling Relative Risk and Heritability of Sjögren’s Syndrome: A Nationwide Population Study in Taiwan
Chang-Fu Kuo¹, Matthew J. Grainge², Kuang-Hui Yu³, Lai-Chu See⁴, Shue-Fen Luo³, Ana M. Valdes⁵, I-Jun Chou⁶, Hsiao-Chun Chang³, Weiya Zhang¹ and Michael Doherty⁷, ¹Academic Rheumatology, School of Clinical Sciences, University of Nottingham, Nottingham, United Kingdom, ²Division of Epidemiology and Public Health, School of Community Health Sciences, University of Nottingham, Nottingham, United Kingdom, ³Division of Rheumatology, Immunology and Allergy, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁴Department of Public Health, College of Medicine, Chang Gung University, Taoyuan, Taiwan, ⁵Dept of Twin Research and Genetic Epidemiology, St. Thomas' Hospital, King's College London, Dept of Twin Research and Genetic Epidemiology, St. Thomas' Hospital, King's College London, London, United Kingdom, ⁶Department of Pediatrics, Chang Gung Memorial Hospital, Taoyuan, Taiwan, ⁷Academic Rheumatology, University of Nottingham, Nottingham, United Kingdom
Background/Purpose: Although familial aggregation has been found in many autoimmune diseases, the evidence for familial aggregation in Sjögren’s syndrome is lacking. The aims of this…
Abstract Number: 2190 • 2012 ACR/ARHP Annual Meeting
Antimalarials for Sjogren’s Syndrome Treatment in Adults, Meta-Analysis
Vibian A. Coy¹, Carlos E. Granados², Diana Gil¹, Alejandro Junca¹, Daniel Jaramillo¹, Antonio A. Iglesias-Gamarra³, Jose Felix Restrepo⁴ and Federico Rondon-Herrera⁴, ¹Facultad de Medicina- Departamento de Medicina-Unidad de Reumatología, Fellow of Rheumatology Universidad Nacional de Colombia, Bogotá, Colombia, ²Departamento de Medicina, facultad de medicina, Professor -Universidad Nacional de Colombia, Bogotá, Colombia, ³Facultad de Medicina- Departamento de Medicina-Unidad de Reumatología, Professor-Universidad Nacional de Colombia, Bogota, Colombia, ⁴Facultad de Medicina- Departamento de Medicina-Unidad de Reumatología, Professor -Universidad Nacional de Colombia, Bogota, Colombia
Background/Purpose: Sjögren´s syndrome (SS) is a chronic inflammatory autoimmune disease that is presented with lymphocytic infiltration of exocrine glands. Its secondary secretory dysfunction may involved…
Abstract Number: 521 • 2012 ACR/ARHP Annual Meeting
Differences in Genome-Wide DNA Methylation Profiles Across Multiple Cell and Tissue Types in Sjögren’s Syndrome (SS)
Lindsey A. Criswell¹, Diana Quach², Hong L. Quach², Emon Elboudwarej² and Lisa F. Barcellos², ¹Rosalind Russell Medical Research Center for Arthritis, Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA, ²Epidemiology, University of California, Berkeley, Berkeley, CA
Background/Purpose: Increasing evidence supports a role for epigenetic factors, including DNA methylation status, in autoimmune disease risk and severity. Our goal is to characterize DNA…
Abstract Number: 2674 • 2012 ACR/ARHP Annual Meeting
Cis-Expression Quantitative Trait Loci Analysis of Dysregulated Interferon-Pathway Genes Identifies HLA-C and OAS1 As Novel Candidates for Susceptibility to Sjögren’s Syndrome
He Li¹, John A. Ice², Jennifer A. Kelly³, Indra Adrianto², Stuart B. Glenn⁴, Kimberly S. Hefner⁵, Evan G. Vista⁶, Donald U. Stone⁷, Raj Gopalakrishnan⁸, Glen D. Houston⁹, David M. Lewis¹⁰, Michael Rohrer⁸, Pamela Hughes⁸, John B. Harley¹¹, Courtney G. Montgomery², James Chodosh⁷, James A. Lessard¹², Juan-Manuel Anaya¹³, Barbara M. Segal¹⁴, Nelson L. Rhodus¹⁵, Lida Radfar¹⁶, Mark B. Frank¹⁷, R. Hal Scofield¹⁸, Christopher J. Lessard¹⁹ and Kathy Moser Sivils³, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵Hefner Eye Care and Optical Center, Oklahoma City, OK, ⁶Rheumatology and Clinical Immunology, University of Santo Tomas, Taguig City, Philippines, ⁷Ophthalmology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁸Diagnostic and Biological Sciences, University of Minnesota, Minneapolis, MN, ⁹Collage of Denistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁰College of Dentistry, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹¹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children's Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹²Valley Bone and Joint Clinic, Grand Forks, ND, ¹³School of Medicine and Health Sciences, Universidad del Rosario. Center for Autoimmune Diseases Research (CREA), Bogotá, Colombia, ¹⁴Rheumatology, Hennepin County Medical Center, Minneapolis, MN, ¹⁵University of Minnesota, Minneapolis, MN, ¹⁶University of Oklahoma Health Sciences Center, Oklahoma City, OK, ¹⁷Arthritis & Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁸Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Sjögren’s syndrome (SS) is a progressive autoimmune exocrinopathy characterized by symptoms of dry eyes and mouth present in 0.7-1% of Europeans. Dysregulation of interferon…
Abstract Number: 2191 • 2012 ACR/ARHP Annual Meeting
Secretagogue Use in Patients with Primary Sjogren’s Syndrome
Ghaith Noaiseh¹, Joshua Baker² and Frederick B. Vivino³, ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Medicine, Penn Presbyt Med Ctr, Philadelphia, PA
Background/Purpose: Secretagogues are commonly used to treat xerostomia in primary Sjogren’s syndrome (pSS). Side effects and/or lack of efficacy sometimes result in cessation of…
Abstract Number: 522 • 2012 ACR/ARHP Annual Meeting
Genetic Variation in the NCR3 Locus Is Associated with Anti-SSA⁄SSB Positive Primary Sjögren′s Syndrome in Scandinavian Samples
Gunnel Nordmark¹, Maija-Leena Eloranta¹, Per Eriksson², Elke Theander³, Helena Forsblad-d'Elia⁴, Roald Omdal⁵, Marie Wahren-Herlenius⁶, Roland Jonsson⁷ and Lars Rönnblom¹, ¹Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, ²Rheumatology/AIR, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, ³Dept of Rheumatology, Skane University Hospital, Lund University, Malmö, Sweden, ⁴Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, ⁵Department of Internal Medicine, Stavanger university Hospital, Stavanger, Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, ⁶Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁷Broegelmann Research Laboratory, the Gade Institute, University of Bergen, Bergen, Norway
Background/Purpose: Candidate gene studies in primary Sjögren’s syndrome (pSS) have identified polymorphisms in genes involved in the type I interferon (IFN) system and the type…
Abstract Number: 2675 • 2012 ACR/ARHP Annual Meeting
Oral and Gut Microbiota Influence Immune Responses to Sjogren’s Syndrome Associated Antigen Ro60
Agnieszka Szymula¹, Barbara Szczerba¹, Harini Bagavant¹, Shu-Man Fu² and Umesh Deshmukh³, ¹Department of Medicine, University of Virginia, Charlottesville, VA, ²University of Virginia, Charlottesville, VA, ³Medicine, University of Virginia, Charlottesville, VA
Background/Purpose: Autoantibodies reactive against Ro60 protein are often found in patients with Sjogren’s syndrome. This study was undertaken to investigate the role of oral and…
Abstract Number: 2192 • 2012 ACR/ARHP Annual Meeting
Phenotypic Features of Sjögren’s Syndrome Among Patients with Low-Titer SSA/B Antibodies
Mara McAdams DeMarco¹, Mi Y. Lam², Stephen Shiboski², Lindsey A. Criswell³, Caroline Shiboski⁴ and Alan N. Baer⁵, ¹Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ²University of California, San Francisco, San Francisco, CA, ³Department of Medicine, University of California, San Francisco, Rosalind Russell Medical Research Center for Arthritis, San Francisco, CA, ⁴Orofacial Sciences, University of California, San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: The significance of a low titer of SSA and/or SSB antibodies (SSA/B-Ab) in individuals with clinical or other laboratory findings suggestive of Sjögren’s syndrome…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].